Autologous Protein Solution(Zimmer Biomet)(Autologous Protein Solution(Zimmer Biomet))

概要

基本信息

药物类型

细胞疗法

别名-

靶点-

作用方式-

作用机制-

治疗领域

皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

膝关节炎

原研机构

Zimmer Biomet Holdings, Inc.

在研机构-

非在研机构

Zimmer Biomet Holdings, Inc.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Autologous Protein Solution(Zimmer Biomet) 相关的临床试验

ACTRN12621000220864

/ Recruiting临床4期

The effect of Autologous Protein Solution on patient reported outcomes in knee osteoarthritis

开始日期2021-06-11

申办/合作机构-

NCT02580643

/ CompletedN/A

Prospective Post-Market Data Collection on Patients With Knee Osteoarthritis and Treated With nSTRIDE Autologous Protein Solution (REGP-22-00)

This study will document treatment effects, changes in quality of life, procedure complications, adverse events, healthcare resource utilization, and further needed intervention(s) following treatment with nSTRIDE autologous protein solution. This study will also allow for the documentation of the same parameters following multiple injections of autologous protein solution to treat knee osteoarthritis.

开始日期2016-05-01

申办/合作机构

Zimmer Biomet Holdings, Inc.

NCT02262364

/ Completed临床1期

A Pilot Study of a Single Intra-articular Injection of Autologous Protein Solution in Patients With Knee Osteoarthritis

The primary objective of this study is to assess the safety of a single injection of APS.

开始日期2014-11-01

申办/合作机构

Zimmer Biomet Holdings, Inc.

[+1]

100 项与 Autologous Protein Solution(Zimmer Biomet) 相关的临床结果

登录后查看更多信息

100 项与 Autologous Protein Solution(Zimmer Biomet) 相关的转化医学

登录后查看更多信息

100 项与 Autologous Protein Solution(Zimmer Biomet) 相关的专利（医药）

登录后查看更多信息

1,408

项与 Autologous Protein Solution(Zimmer Biomet) 相关的文献（医药）

2025-06-01·Fish & Shellfish Immunology

Eucommia ulmoides leaf extracts combined with Astragalus polysaccharides: Effects on growth, antioxidant capacity, and intestinal inflammation in juvenile large yellow croaker (Larimichthys crocea)

Article

作者: Qi, Qiong ; Zhang, Jiaonan ; Li, Changhui ; Shao, Jianchun ; Chen, Xiaojuan ; Lv, Huiyuan ; Chen, Xinhua ; Wang, Xuexi ; Liu, Qianqian

Eucommia ulmoides leaf extract (ELE) and Astragalus polysaccharides (APS) have been widely used as immunopotentiators in aquaculture. Our prior research on large yellow croaker (Larimichthys crocea) demonstrated that dietary 1 g/kg APS bolstered fish immunity and antioxidant defense. However, the combined effect of ELE and APS in juvenile large yellow croaker remains unknown. Hence, this study aimed to investigate the synergistic effect of ELE and APS on the growth, antioxidant capacity, and intestinal inflammation in large yellow croaker. A total of 1200 fish were divided into five groups and fed diets with 1 g/kg APS and varying ELE levels: 0 g/kg (ELE0), 0.25 g/kg (ELE0.25), 0.5 g/kg (ELE0.5), 1 g/kg (ELE1), and 2 g/kg (ELE2). After an 8-week feeding period, the ELE0.5 and ELE1 groups showed superior weight gain rate, specific growth rate, and feed efficiency compared to other groups. The ELE1 group also had elevated trypsin and lipase activities in the intestine, whereas α-amylase activity was not influenced by ELE addition. Antioxidant enzyme activities, such as hepatopancreas superoxide dismutase (SOD) and glutathione peroxidase (GPX) in the ELE1 group were significantly enhanced, while malondialdehyde (MDA) levels decreased with increasing ELE. Intestinal morphology revealed the highest villi height in proximal and distal intestines of ELE1 group, with no significant change in mucosal thickness. In terms of cytokines, the ELE1 group showed significant down-regulation of pro-inflammatory (tnf-α, il-1β and il-6) and up-regulation of anti-inflammatory (il-4/13a, il-10 and tgf-β) markers, modulated by MAPK and mTOR signaling. In conclusion, this study indicates that supplementing diets with 1 g/kg ELE alongside 1 g/kg APS in juvenile large yellow croaker offers the best synergistic effect on fish immunity, including enhanced growth, antioxidant capacity, and relieved intestinal inflammation through MAPK and mTOR signaling.

2025-04-01·Journal of Neuroscience Methods

A method for HDAC activity screening in postmortem human brain. A proof-of-concept study with antipsychotics

Article

作者: Muguruza, Carolina ; Rivero, Guadalupe ; Ramos-Miguel, Alfredo ; Meana, J Javier ; Callado, Luis F ; Martínez-Peula, Oihane

BACKGROUNDHistone deacetylase (HDAC) density and activity are altered in different brain disorders. Antipsychotic drugs (APs) might modulate HDAC activity in brains of schizophrenia subjects.NEW METHODHDAC activity assay amenable for enzyme kinetics and HDAC inhibitor (HDACi) screening studies in postmortem human brain samples.RESULTSThe optimization and characterization work involved several steps. The nucleosolic subcellular fraction and total protein amount needed for an optimal HDAC activity on Boc-Lys(Ac)-AMC substrate were characterized. Signal-to-noise ratio (1.8) and Z-score values (0.82) were indicators of the assay quality. Inhibition studies with non-selective (belinostat, vorinostat, valproic acid) and selective (apicidin, MS275, romidepsin, tacedinaline and EX527) HDACis showed that the optimized assay detected class I HDAC activity. The obtained IC50 values were similar to those previously reported, proving the assay reliability. We used the optimized assay to study the effect of APs on HDAC activity. Inhibition studies with APs in postmortem human brain, together with enzyme kinetic studies in brains of rats chronically treated with APs observed no modulation of class I HDAC activity.COMPARISON WITH EXISTING METHODSThis study describes the optimization of a reliable and cost efficient HDAC activity assay for its use in postmortem human brain samples. The assay does not depend on antibody specificity and it is valid for enzyme kinetic studies and for the screening of new potential class I HDACis.CONCLUSIONSWe optimized and characterized an assay to measure HDAC activity in postmortem human brain samples. We did not observe any modulatory effect of APs on HDAC activity.

2025-04-01·International Journal of Biological Macromolecules

Astragalus polysaccharide reduces the severity of acute pancreatitis under a high-fat diet through enriching L. reuteri and propionate

Article

作者: Du, Zhiwei ; Wang, Liyi ; Zheng, Yi ; Lv, Zhenyi ; Liu, Xuxu ; Meng, Ziang ; Xue, Dongbo ; Wang, Qiang

Acute pancreatitis (AP) is a severe digestive disorder, worsened by a high-fat diet (HFD) through inflammation and gut microbiota disruption. Astragalus polysaccharides (APS), known for their anti-inflammatory properties, may alleviate HFD-induced exacerbation of AP by modulating gut microbiota. This study investigates the effect of APS on AP severity under a HFD (HAP). Results show that HFD significantly worsens AP, with elevated serum enzymes, pro-inflammatory cytokines, and pancreatic damage. Single-cell RNA sequencing revealed increased ICAM1⁺ neutrophils and activation of the NF-κB/necroptosis pathway in HAP mice. Treatment with APS reduced neutrophil infiltration, downregulated NF-κB, and suppressed necroptosis. APS also restored gut microbiota balance, boosting Lactobacillus reuteri (L. reuteri) and propionate (PA) levels. Interventions with L. reuteri or PA reduced HAP severity, with combined treatment showing synergistic effects. These findings suggest that the protective effect of APS is mediated by microbiota-dependent mechanisms, highlighting the gut-pancreas axis as a potential therapeutic target for AP.

100 项与 Autologous Protein Solution(Zimmer Biomet) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床1期	美国	Zimmer Biomet Holdings, Inc.	2014-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02262364 (CTgov)	临床1期	膝关节炎	11	APS	(網鏇鹽鹽積夢淵觸鑰齋) = 鏇網選簾範鹽範蓋範顧鑰鹹醖鹹廠鑰鑰構鹹夢 (顧製簾繭淵壓衊衊獵蓋, 艱鹽構鏇餘鹹廠餘願憲 ~ 鬱築淵鏇築觸繭繭築窪) 更多	-	2019-02-15
EULAR2017	N/A	系统性红斑狼疮 \| 抗磷脂综合征 antiphospholipid antibodies	22	HCQ naïve-patients with persistent aPL or APS	窪願鏇觸鏇範醖範願遞(憲夢廠選築願鹹簾遞窪) = 繭憲獵淵構鬱鑰襯衊淵鏇顧鹹鹽鏇襯顧鹹鹹窪 (鏇簾鹽選窪鏇夢壓鏇襯, 108)	积极	2017-06-14